DOCSLIB.ORG

Pharmacotherapy of Tinea Capitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacotherapy of Tinea Capitis J Am Board Fam Pract: first published as 10.3122/jabfm.12.3.236 on 1 May 1999. Downloaded from STEPPED CARE: AN EVIDENCE-BASED APPROACH TO DRUG THERAPY Pharmacotherapy of Tinea Capitis Mary E. Temple, PharmD, Milap C. Nahata, PharmD, and Katalin I. Koranyi, MD Editors' Note: This month we continue the new feature­ dans do. We will avoid making conclusions that are not sup­ STEPped Care: An Evidence-BasedApproach to Drug Ther­ ported by POEMs. Nevertheless, POEMs should be incorpo­ apy. These articles are designed to provide concise answers to rated into clinical practice. The rest is up to the reader. Blend­ the drog therapy questions that family physicians encounter in ing POEMs with rational thought, clinical experience, and their daily practice. The format ofthe feature will folhw the importantly, patient preferences can be the essence ofthe art mnemonic STEP: safety (an analysis ofadverse effects that ofmedicine. patients and providers care about), tolerability (pooled drop­ We hope you will find these new articles useful and easy to out rates from large clinical trials), effectiveness (how well the read. Your comments and suggestions are wekome. You may drogs work and in what patient population[sj), and price contact the editors through the editorial office ofJABFP or on (costs ofdrog, but also cost-effectiveness oftherapy). 1 Hence, the Internet (http://clinic.isu.edu/drogsteps/intro.html). the name STEPped Care. We hope the articles provide you with useful information that Since the informatics pioneers at McMaster University can be applied in everyday practice, and we look forward to introduced evidence-based medicine,2 Slawson and col­ your feedback. leagues3,4 have brought it to mainstream family medicine ed­ ucation and practice. This feature is designed to further the Rex W. Force, PhannD, STEPped Care Feature Editor mission ofsearchingfor the troth in medical practice. Authors John P. Geyman, MD, Editor will provide information in a stroctured format that allows Journal ofthe American Board ofFamily Practice the readers to get to the meat ofa therapeutic issue in a way References that can help physicians (and patients) make informed deci­ 1. Shaughnessy AF, Slawson DC, Bennett)H. Separating the wheat from the chaff: identifying fallacies in pharmaceutical sions. The articles will discourage the use ofdisease-oriented promotion.) Gen Intern Mea 1994;9:563-8. evidence (DOE) to make treatment decisions. Examples of 2. Evidence-based medicine: a new approach to teaching the DOEr include blood pressure hwering, decreases in hemoglobin practice of medicine. Evidence-Based Medicine Working Group.)AMA 1992;268:2420-5. A Ie, and SO on. We will include studies that are POEMs-pa­ 3. Slawson DC, Shaughnessy AF, Bennett )H. Becoming a tient-oriented evidence that matters (myocardial infarctions, medical information master: feeling good about not know­ ing everything.) Fam Pract 1994;38:505-13. pain, strokes, mortality, etc)-with the goal ofoffering our 4. Shaughnessy AF, Slawson DC, Bennett)H. Becoming an in­ http://www.jabfm.org/ patients the most practical, appropriate, and scientifically sub­ formation master: a guidebook to the medical information stantiated therapies. Number needed to treat to observe benefit jungle.) Fam Pract 1994;39:489-99. 5. Laupacis A. Sackett DL, Roberts RS. An assessment of clini­ in a single patient will also be included as a way ofdefining cally: useful measures of the consequences of treatment. N advantages in terms that are relatively easy to understand. ),6 Engl) Med 1988;318:1728-33. 6. Wtffen P), Moore RA. Demonstrating effectiveness-the At times this effort will be frustrating. Even as vast as the concept of numbers-needed-to-treat. J Clin Pharm Ther biomedical literature is, it does not always support what clini- 1996;21:23-7. on 27 September 2021 by guest. Protected copyright. Tinea capitis, or ringworm of the scalp, is the capitis is transmitted by humans (anthropophilic) most common dermatophyte infection in pedi­ or is acquired from animals (zoophilic). Trichophy­ atric populations throughout the world. 1-4 In the ton tonsurans and Microsporum audouinii are associ­ United States, 3 to 8 percent of the population can ated with anthropophilic infections, and Microspo­ be affected. 5-7 Additionally, 34 percent of house­ rum canis is associated with zoophilic infections.9•IO hold contacts of children with tinea capitis are In the United States T tonsurans has replaced asymptomatic carriers of the infection.8 Tinea M audouinii as the most common pathogen, and it causes up to 96 percent of tinea capitis infec­ tions. II Generally, Trichophyton infections are Submitted, revised, 3 February 1999. equally distributed between boys and girls and From the College of Pharmacy (MET, MCN) the Depart­ ment of Pediatrics, College of Medicine (MCN, KIK), and affect far more African-Americans than whites. Children's Hospital (MET, MCN, KIK), The Ohio State The infection is rare in adults and adolescents University, Columbus. Address reprints requests to Milap C. Nahata, PharmD, College of Pharmacy, The Ohio State Uni­ (who have reached puberty), although they can versity, 500 West 12th Ave, Columbus, OH 43210. be carriers. The rarity of infection is most likely 236 JABFP May-June 1999 Vol. 12 No.3 J Am Board Fam Pract: first published as 10.3122/jabfm.12.3.236 on 1 May 1999. Downloaded from attributed to the fungistatic activity of short- and approach. The STEP approach involves: safety long-chain fatty acids found in the sebum of (analysis of adverse events most concerning to pa­ these individuals.3.5.7 tients and physicians), tolerability (pooled drop­ Although griseofulvin is the only agent ap­ out rates from large clinical trials), effectiveness proved for the treatment of tinea capitis by the (the efficacy of medications and what patient pop­ Food and Drug Administration, (FDA) a variety ulations benefit most), and price (cost of drug, but of other systemic and topical agents, including ke­ also cost effectiveness of therapy). toconazole, itraconazole, fluconazole, terbinafine, corticosteroids, and selenium sulfide, are also be­ Safety and Tolerability ing used. Griseofulvin is fungistatic and acts by in­ Treatment of tinea capitis usually requires ex­ terfering with fungal nucleic acid synthesis. 12 Ke­ tended therapy with medications that can cause toconazole, itraconazole, and fluconazole are all adverse reactions in some patients. In a 12-week fungistatic and inhibit the biosynthesis of fungal randomized double-blind study, 79 patients (most ergosterol. 13 Terbinafine is the only systemic were African-Americans) were given griseofulvin agent that is fungicidal at low concentrations and microsize (n - 46) or ketoconazole (n - 33).16 Al­ acts by inhibiting squalene epoxide and thus er­ though 6 percent of patients taking griseofulvin gosterol biosynthesis.14 developed mild elevations in aspartate amino­ Adjunctive agents used in the treatment of transferase, these elevations were not of clinical tinea capitis include corticosteroids and selenium importance as patients continued on therapy. Two sulfide. Corticosteroids are used to alter the host patients (6 percent) in the ketoconazole group and immune-mediated responses in patients with 3 (6.5 percent) in the griseofulvin group withdrew complicated tinea capitis, whereas selenium sul­ for unknown reasons. An additional patient on ke­ fide is used as a topical sporicidal agent. 15 toconazole withdrew from the study because of The focus of tinea capitis literature has been nausea. largely disease oriented. Most studies have evalu­ A 6-week double-blind study comparing keto­ ated the microbiologic response to certain agents conazole (n - 24) with griseofulvin microsize (n - using disease-oriented evidence as surrogates. 23) in 47 children with dermatophyte infections There are some studies, however, that can provide found a twofold increase in serum alanine and as­ POEMs (patient-oriented evidence that matters, partate aminotransferase concentrations after 3 eg, compliance rates and clinical cure, such as hair weeks of treatment in 1 patient on griseofulvin; http://www.jabfm.org/ regrowth, decreased inflammation, and relapse however, concentrations returned to normal in rates) for comparative purposes. 16-30 subsequent visits. No adverse events were re­ ported in the ketoconazole group.17 Methods In a double-blind, randomized study of 35 pa­ MEDLINE and Metacrawler search engines en­ tients given ultramicronized griseofulvin (n - 17) compassing January 1966 through July 1998 were or itraconazole (n - 18), 12 percent of patients tak­ on 27 September 2021 by guest. Protected copyright. used to obtain clinical trials and general informa­ ing griseofulvin discontinued therapy because of tion regarding the treatment of tinea capitis. severe nausea, vomiting, and abdominal pain.ls Search terms included "tinea capitis," "griseoful­ These symptoms resolved after stopping griseo­ vin," "ketoconazole," "itraconazole," "flucona­ fulvin. Although no adverse events were noted zole," "terbinafine," "selenium," "corticosteroids," with itraconazole, 1 patient dropped out for an "antifungal," "trichophyton," and "microsporum." unstated reason. The searches were limited to human clinical trials, Although headache and gastrointestinal dis­ pediatric patients, and review articles published in tress are the most commonly reported adverse ef­ English language journals. Randomized, con­ fects of griseofulvin, rare cases of systemic lupus, trolled studies were included
Load more

Recommended publications
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies
    molecules Article Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies Pradeep Kumar Bolla 1 , Carlos A. Meraz 1, Victor A. Rodriguez 1, Isaac Deaguero 1, Mahima Singh 2 , Venkata Kashyap Yellepeddi 3,4 and Jwala Renukuntla 5,* 1 Department of Biomedical Engineering, College of Engineering, The University of Texas at El Paso, 500 W University Ave, El Paso, TX 79968, USA 2 Department of Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA 3 Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT 84112, USA 4 Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA 5 Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27240, USA * Correspondence: [email protected] Received: 9 August 2019; Accepted: 28 August 2019; Published: 29 August 2019 Abstract: Global incidence of superficial fungal infections caused by dermatophytes is high and affects around 40 million people. It is the fourth most common cause of infection. Clotrimazole, a broad spectrum imidazole antifungal agent is widely used to treat fungal infections. Conventional topical formulations of clotrimazole are intended to treat infections by effective penetration of drugs into the stratum corneum. However, drawbacks such as poor dermal bioavailability, poor penetration, and variable drug levels limit the efficiency. The present study aims to load clotrimazole into ufosomes and evaluate its topical bioavailability. Clotrimazole loaded ufosomes were prepared using cholesterol and sodium oleate by thin film hydration technique and evaluated for size, polydispersity index, and entrapment efficiency to obtain optimized formulation.
    [Show full text]
  • Terbinafine-Induced Taste Impairment - Report of Two Cases Rajesh Sinha, Pallavi Sharma, Pramod Kumar, Vaibhav Kuchhal*
    Journal of Pakistan Association of Dermatologists 2012; 22 (4):363-365. Case Report Terbinafine-induced taste impairment - report of two cases Rajesh Sinha, Pallavi Sharma, Pramod Kumar, Vaibhav Kuchhal* Department of Skin &V.D., Government Medical College, Haldwani 263139, Uttarakhand, India *Department of E.N.T., Government Medical College, Haldwani 263139, Uttarakhand, India Abstract Terbinafine is an oral antimycotic agent that belongs to the allylamine class. It was introduced in 1991 and is being widely used, both topically and systemically, to treat fungal infections. Nowadays oral terbinafine has become a commonly prescribed drug to treat finger- and toenail fungal infections because of relatively short duration of treatment compared to other oral antifungals like griseofulvin and fluconazole. The common side effects of this drug include nausea, abdominal pain, elevated transaminases and allergic reactions. Loss of taste sensation is a rare side effect occurring in patient taking oral form of this drug. PubMed search showed that very few cases of terbinafine- induced taste loss have been reported worldwide. We report a case series of two patients who complained of taste loss after taking terbinafine. Key words Terbinafine, ageusia. Introduction terbinafine that occurs in 0.6% to 2.8% of patients taking the drug. A low BMI, ageing Terbinafine is a widely prescribed oral and history of taste loss are considered risk antifungal agent. Its mode of action is by factors for developing taste loss due to inhibiting squalene epoxidase which converts terbinafine. squalene to lanosterol. With a decrease in lanosterol production, ergosterol production is Case report 1 also diminished, affecting fungal cell membrane synthesis and function.
    [Show full text]
  • Voriconazole
    Drug and Biologic Coverage Policy Effective Date ............................................ 6/1/2020 Next Review Date… ..................................... 6/1/2021 Coverage Policy Number .................................. 4004 Voriconazole Table of Contents Related Coverage Resources Coverage Policy ................................................... 1 FDA Approved Indications ................................... 2 Recommended Dosing ........................................ 2 General Background ............................................ 2 Coding/Billing Information .................................... 4 References .......................................................... 4 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion
    [Show full text]
  • Producing In-Situ Nanoparticles of Griseofulvin Using Supercritical Antisolvent Methodology
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 2013 Producing In-Situ Nanoparticles of Griseofulvin using Supercritical Antisolvent Methodology Pratik Sheth University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Sheth, Pratik, "Producing In-Situ Nanoparticles of Griseofulvin using Supercritical Antisolvent Methodology" (2013). Open Access Dissertations. Paper 25. https://digitalcommons.uri.edu/oa_diss/25 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. PRODUCING IN-SITU NANOPARTICLES OF GRISEOFULVIN USING SUPERCRITICAL ANTISOLVENT METHODOLOGY BY PRATIK SHETH A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN BIOMEDICAL AND PHARMACEUTICAL SCIENCES UNIVERSITY OF RHODE ISLAND 2013 DOCTOR OF PHILOSOPHY DISSERTATION OF PRATIK SHETH APPROVED: Dissertation Committee: Major Professor M. Serpil Kislalioglu Ph.D David Worthen Ph.D. Michael L. Greenfield Ph.D Nasser H. Zawia Ph.D DEAN OF THE GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2013 ABSTRACT Poor aqueous solubility of drug candidates is a major challenge for the pharmaceutical scientists involved in drug development. Particle size reduction to nano scale appears as an effective and versatile option for
    [Show full text]
  • Long-Term Effectiveness of Treatment with Terbinafine Vs Itraconazole in Onychomycosis a 5-Year Blinded Prospective Follow-Up Study
    STUDY Long-term Effectiveness of Treatment With Terbinafine vs Itraconazole in Onychomycosis A 5-Year Blinded Prospective Follow-up Study Ba´rður Sigurgeirsson, MD, PhD; Jo´n H. O´ lafsson, MD, PhD; Jo´n þ. Steinsson, MD Carle Paul, MD; Stephan Billstein, MD; E. Glyn V. Evans, PhD Objective: To examine long-term cure and relapse rates microscopy and culture at the end of follow-up and no re- after treatment with continuous terbinafine and inter- quirement of second intervention treatment. Secondary ef- mittent itraconazole in onychomycosis. ficacy criteria included clinical cure without second inter- vention treatment and mycological and clinical relapse rates. Design: Long-term prospective follow-up study. Results: Median duration of follow-up was 54 months. Setting: Three centers in Iceland. At the end of the study, mycological cure without second intervention treatment was found in 34 (46%) of the 74 Subjects: The study population comprised 151 pa- terbinafine-treated subjects and 10 (13%) of the 77 itra- tients aged 18 to 75 years with a clinical and mycologi- conazole-treated subjects (PϽ.001). Mycological and clini- cal diagnosis of dermatophyte toenail onychomycosis. cal relapse rates were significantly higher in itraconazole- vs terbinafine-treated patients (53% vs 23% and 48% vs Interventions: In a double-blind, double-dummy study, 21%, respectively). Of the 72 patients who received sub- patients were randomized to receive either terbinafine (250 sequent terbinafine treatment, 63 (88%) achieved myco- mg/d) for 12 or 16 weeks or itraconazole (400 mg/d) for logical cure and 55 (76%) achieved clinical cure. 1 week in every 4 for 12 or 16 weeks (first intervention).
    [Show full text]
  • UTROGESTAN 100Mg Capsules Progesterone
    NEW ZEALAND DATA SHEET UTROGESTAN 100mg capsules Progesterone 1 PRODUCT NAME UTROGESTAN 100MG CAPSULES 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Soft, round, slightly yellow capsule containing a whitish oily suspension of 100 mg progesterone (micronised). Excipient(s) with known effect: Soya lecithin For full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Capsules, soft 4 CLINICAL PARTICULARS 4.1 Therapeutic indications UTROGESTAN 100 mg capsule is indicated in adults, via the oral route, for: Hormone replacement therapy • Adjunctive use with an oestrogen in postmenopausal women with an intact uterus (for hormone replacement therapy [HRT]) 4.2 Dose and method of administration Dosage The recommended dose is as follows, according to the indication: Oral Route • In the treatment of menopause: oestrogen alone therapy is not recommended on its own in menopausal women with an intact uterus. The usual dose is 200 mg/day at bedtime at least 12 to 14 days per month, i.e. on days 15 to 26 of each cycle or in the last 2 weeks of each treatment sequence of oestrogen therapyfollowed by approximately one week without any replacement therapy and during which withdrawal bleeding may occur. Alternatively 100 mg can be given at bedtime, from days 1 to 25 of each cycle, withdrawal bleeding being less with this treatment schedule. Method of Administration This product is intended only for oral use. UTROGESTAN 100 mg should not be taken with food; it is preferable to take the capsules in the evening at bedtime. UTROGESTAN 100mg caps UTROGEST005 Jan 2018 Page 1 of 9 NEW ZEALAND DATA SHEET Oral Route Each capsule of UTROGESTAN 100 mg must be swallowed with a little water.
    [Show full text]
  • Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut
    ■ CLINICAL REVIEW Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut Tinea versicolor (pityriasis versicolor) is a common imidazole, has been used for years both orally and top­ superficial fungal infection of the stratum corneum. ically with great success, although it has not been Caused by the fungus Malassezia furfur, this chronical­ approved by the Food and Drug Administration for the ly recurring disease is most prevalent in the tropics but indication of tinea versicolor. Newer derivatives, such is also common in temperate climates. Treatments are as fluconazole and itraconazole, have recently been available and cure rates are high, although recurrences introduced. Side effects associated with these triazoles are common. Traditional topical agents such as seleni­ tend to be minor and low in incidence. Except for keto­ um sulfide are effective, but recurrence following treat­ conazole, oral antifungals carry a low risk of hepato- ment with these agents is likely and often rapid. toxicity. Currently, therapeutic interest is focused on synthetic Key Words: Tinea versicolor; pityriasis versicolor; anti­ “-azole” antifungal drugs, which interfere with the sterol fungal agents. metabolism of the infectious agent. Ketoconazole, an (J Fam Pract 1996; 43:127-132) ormal skin flora includes two morpho­ than formerly thought. In one study, children under logically discrete lipophilic yeasts: a age 14 represented nearly 5% of confirmed cases spherical form, Pityrosporum orbicu- of the disease.3 In many of these cases, the face lare, and an ovoid form, Pityrosporum was involved, a rare manifestation of the disease in ovale. Whether these are separate enti­ adults.1 The condition is most prevalent in tropical tiesN or different morphologic forms in the cell and semitropical areas, where up to 40% of some cycle of the same organism remains unclear.: In the populations are affected.
    [Show full text]
  • Divestra Leaflet
    • Known or suspected estrogen-dependent neoplasia Drugs which may decrease the therapeutic effect of Cyproterone acetate+Ethinyl Pregnancy and Breastfeeding • Undiagnosed abnormal vaginal bleeding Combination of Cyproterone acetate and Ethinyl estradiol is contraindicated during estradiol and increase the incidence of breakthrough bleeding • Any ocular lesion arising from ophthalmic vascular disease, such as partial or complete pregnancy and breastfeeding. loss of vision or defect in visual fields Effects on ability to drive and use machines • Concomitant use with other Estrogen+Progestogen combinations or estrogens or Unknown progestogens alone • When pregnancy is suspected or diagnosed Adverse Reactions • Severe diabetes with vascular changes Common adverse reactions includes headaches, nausea, abdominal pain, weight gain, • A history of otosclerosis with deterioration during pregnancy depressed or altered mood and breast pain or tenderness. • Hypersensitivity to this drug or to any ingredient in the formulation or component of the Uncommon adverse reactions include vomiting, diarrhea, fluid retention and migraine. container. Overdose (Cyproterone acetate + Warnings and Precautions There is no antidote and treatment should be symptomatic. Ethinyl estradiol) Discontinue Cyproterone acetate+Ethinyl estradiol tablets at the earliest manifestation of the following: PHARMACOLOGICAL PROPERTIES • Thromboembolic and Cardiovascular Disorders such as thrombophlebitis, pulmonary Pharmacotherapeutic group: Sex hormones and modulators of the genital system, QUALITATIVE AND QUANTITATIVE COMPOSITION embolism, cerebrovascular disorders, myocardial ischemia, mesenteric thrombosis, and anti-androgens and estrogens. ATC code: G03HB01 Each film-coated tablet contains: retinal thrombosis. Cyproterone acetate (Ph.Eur.)………...2 mg • Conditions that predispose to Venous Stasis and to Vascular Thrombosis (eg. Mechanism of action Ethinyl estradiol (USP)……………...0.035 mg immobilization after accidents or confinement to bed during long-term illness).
    [Show full text]
  • Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-Use Date
    PEER REVIEWED Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-use Date ABSTRACT Pradeep Gautam, MS Chemistry A novel compounding vehicle (RECURA) has previously been proven to Bob Light, BS, RPh penetrate the nail bed when compounded with the antifungal agent miconazole or fluconazole, providing for an effective treatment for onychomycosis. In this Troy Purvis, PhD study, miconazole and fluconazole were compounded separately in RECURA compounding cream, and they were tested at different time points (0, 7, 14, 28, 45, 60, 90, and 180 days), determining the beyond-use date of those INTRODUCTION formulations. The beyond-use date testing of both formulations (10% Onychomycosis is a fungal infection of miconazole in RECURA and 10% fluconazole in RECURA) proved them to be the nail bed in the fingers, or more com- physically, chemically, and microbiologically stable under International monly the toes, which affects an estimated Conference of Harmonisation controlled room temperature (25°C ± 2°C/60% 1 10% of the world’s population. Trichophy- RH ±5%) for at least 180 days from the date of compounding. Stability- ton is the typical fungal genus that causes indicating analytical method validation was completed for the simultaneous these infections in Western countries, while determination of miconazole and fluconazole in RECURA base using high- those living tropical regions experience Candida, Aspergillus, or Scytaldium infec- performance liquid chromatography coupled with photodiode array detector tion,2 but the symptoms of these infections prior to the study. are similar across the board. Minor infec- tion causes a yellow or black thickening of the nail bed, while further progression can 48% cure rate),1 yet concern about long- These medications must be in direct contact result in the nail chipping away and leaving term dosing and severe side-effects due to with the fungus in order to kill it.5 The FDA- an open sore, leading to secondary infec- oral administration exists.
    [Show full text]
  • The Epidemiology and Clinical Features of Balamuthia Mandrillaris Disease in the United States, 1974 – 2016
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Clin Infect Manuscript Author Dis. Author manuscript; Manuscript Author available in PMC 2020 August 28. Published in final edited form as: Clin Infect Dis. 2019 May 17; 68(11): 1815–1822. doi:10.1093/cid/ciy813. The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974 – 2016 Jennifer R. Cope1, Janet Landa1,2, Hannah Nethercut1,3, Sarah A. Collier1, Carol Glaser4, Melanie Moser5, Raghuveer Puttagunta1, Jonathan S. Yoder1, Ibne K. Ali1, Sharon L. Roy6 1Waterborne Disease Prevention Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA 2James A. Ferguson Emerging Infectious Diseases Fellowship Program, Baltimore, MD, USA 3Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA 4Kaiser Permanente, San Francisco, CA, USA 5Office of Financial Resources, Centers for Disease Control and Prevention Atlanta, GA, USA 6Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA Abstract Background—Balamuthia mandrillaris is a free-living ameba that causes rare, nearly always fatal disease in humans and animals worldwide. B. mandrillaris has been isolated from soil, dust, and water. Initial entry of Balamuthia into the body is likely via the skin or lungs. To date, only individual case reports and small case series have been published. Methods—The Centers for Disease Control and Prevention (CDC) maintains a free-living ameba (FLA) registry and laboratory. To be entered into the registry, a Balamuthia case must be laboratory-confirmed.
    [Show full text]
  • DIFLUCAN® (Fluconazole Tablets) (Fluconazole for Oral Suspension)
    ® DIFLUCAN (Fluconazole Tablets) (Fluconazole for Oral Suspension) DESCRIPTION DIFLUCAN® (fluconazole), the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration, as a powder for oral suspension. Fluconazole is designated chemically as 2,4-difluoro-α,α1-bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with an empirical formula of C13H12F2N6O and molecular weight of 306.3. The structural formula is: OH N N N N CH2 C CH2 N F N F Fluconazole is a white crystalline solid which is slightly soluble in water and saline. DIFLUCAN Tablets contain 50 mg, 100 mg, 150 mg, or 200 mg of fluconazole and the following inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, povidone, croscarmellose sodium, FD&C Red No. 40 aluminum lake dye, and magnesium stearate. DIFLUCAN for Oral Suspension contains 350 mg or 1400 mg of fluconazole and the following inactive ingredients: sucrose, sodium citrate dihydrate, citric acid anhydrous, sodium benzoate, titanium dioxide, colloidal silicon dioxide, xanthan gum, and natural orange flavor. After reconstitution with 24 mL of distilled water or Purified Water (USP), each mL of reconstituted suspension contains 10 mg or 40 mg of fluconazole. CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral routes. In normal volunteers, the bioavailability of orally administered fluconazole is over 90% compared with intravenous administration. Bioequivalence was Reference ID: 4387685 established between the 100 mg tablet and both suspension strengths when administered as a single 200 mg dose. Peak plasma concentrations (Cmax) in fasted normal volunteers occur between 1 and 2 hours with a terminal plasma elimination half-life of approximately 30 hours (range: 20 to 50 hours) after oral administration.
    [Show full text]